XWELL Announces Closing of $4 Million Private Placement Consisting of Convertible Preferred Stock and Warrants
15 Gennaio 2025 - 2:30PM
XWELL, Inc. (Nasdaq: XWEL) ("XWELL" or the "Company"), an authority
in wellness solutions for people on the go, today announced the
closing of its private placement offering of $4 million of the
Company’s newly designated Series G Convertible Preferred Stock.
The Company also issued to the investors in the private placement
Series A warrants and Series B warrants exercisable for the
Company’s common stock.
The gross proceeds of the private placement were
approximately $4.0 million, before deducting other offering
expenses payable by the Company. XWELL intends to use the net
proceeds of this private placement for working capital and general
corporate purposes as part of the strategy outlined in the
shareholder letter dated December 5, 2024.
“This funding will empower us to advance the
development and deployment of innovative AI-driven health,
wellness, and beauty products,” said CEO Ezra Ernst. “It will also
support the continued expansion of our XWELL locations beyond
airports and enable us to further enhance our integrated branding
efforts. This move proves that we are already activating against
the strategy set forth in late 2024.”
The securities offered in the private placement
consist of 4,000 shares of Series G Convertible Preferred Stock
with an initial conversion price equal to $1.496, Series A warrants
exercisable at a price equal to $1.496, and Series B warrants
exercisable at a price equal to $1.7952. Both the Series A warrants
and Series B warrants are exercisable immediately and expire five
years from the date of issuance.
The securities offered and sold by XWELL in the
private placement were offered and sold in transactions exempt from
the registration requirements of the Securities Act of 1933, as
amended (the “Securities Act”), pursuant to the exemption for
transactions by an issuer not involving any public offering under
Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D
of the Securities Act and in reliance on similar exemptions under
applicable state laws. Accordingly, the securities and underlying
shares of common stock may not be offered or sold in the United
States except pursuant to an effective registration statement or an
applicable exemption from the registration requirements of the
Securities Act and such applicable state securities laws. The
Company has agreed to file a registration statement with the
Securities and Exchange Commission registering the resale of the
shares of common stock issuable upon conversion of the Series G
Convertible Preferred Stock and exercise of the related warrants
issued in connection with the private placement.
The full conversion of the Series G Convertible
Preferred Stock and the full exercise of the accompanying warrants
are subject to stockholder approval. Additional information
regarding the Convertible Preferred Stock and Warrants will be
included in a Current Report on Form 8-K to be filed with the U.S.
Securities and Exchange Commission.
This press release does not constitute an offer
to sell or a solicitation of an offer to buy the securities in this
private placement, nor shall there be any sale of these securities
in any state or other jurisdiction in which such offer,
solicitation or sale would be unlawful prior to the registration or
qualification under the securities laws of any such state or other
jurisdiction.
About XWELL, Inc.
XWELL, Inc. (Nasdaq: XWEL) is a leading global
wellness holding company operating multiple brands: XpresSpa®,
Treat™, Naples Wax Center®, XpresCheck® and HyperPointe™.
- XpresSpa is a leading retailer of
wellness services and related products.
- Naples Wax Center is a group of
upscale skin care boutiques.
- XpresCheck, in partnership with the
CDC and Ginkgo Biosecurity, conducts biosurveillance monitoring in
its airport locations to identify new SARS-CoV-2 variants of
interest and concern as well as other pathogens entering the
country from across the world.
- HyperPointe is a leading digital
healthcare and data analytics relationship company serving the
global healthcare industry.
Forward-Looking Statements
This press release may contain "forward-looking"
statements within the meaning of the Private Securities Litigation
Reform Act of 1995, Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. These include statements preceded by, followed by or that
otherwise include the words "believes," "expects," "anticipates,"
"estimates," "projects," "intends," "should," "seeks," "future,"
"continue," or the negative of such terms, or other comparable
terminology. Important factors that could cause actual results to
differ materially from those indicated by such forward-looking
statements include, without limitation: the anticipated use of
proceeds from the private placement. Forward-looking statements
relating to expectations about future results or events are based
upon information available to XWELL as of the date of this press
release, and are not guarantees of the future performance of the
Company, and actual results may vary materially from the results
and expectations discussed. Additional information concerning these
and other risks is contained in the Company’s Annual Report on Form
10-K, as amended, Quarterly Reports on Form 10-Q and Current
Reports on Form 8-K, and other Securities and Exchange
Commission filings. All subsequent written and oral
forward-looking statements concerning XWELL, or other matters and
attributable to XWELL or any person acting on its behalf are
expressly qualified in their entirety by the cautionary statements
above. XWELL does not undertake any obligation to publicly update
any of these forward-looking statements to reflect events or
circumstances that may arise after the date hereof.
Media
Maria Kucinski
MWW
mkucinski@mww.com
Grafico Azioni XWELL (NASDAQ:XWEL)
Storico
Da Dic 2024 a Gen 2025
Grafico Azioni XWELL (NASDAQ:XWEL)
Storico
Da Gen 2024 a Gen 2025